Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy

NCT05139680 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05139680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05139680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
March 8, 2023
Completion date
May 19, 2023
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary transthyretin amyloidosis (attrv) cardiomyopathy (cm), mixed phenotype